Ajanta Pharma promoter entities sell 4.3% stake for Rs 637 crore

Promoter entities of Ajanta Pharma on Thursday divested 4.3 per cent stake in the company for Rs 637 crore through open market transactions

Medicines, Pharma
Press Trust of India New Delhi
1 min read Last Updated : Dec 22 2022 | 10:35 PM IST

Don't want to miss the best from Business Standard?

Promoter entities of Ajanta Pharma on Thursday divested 4.3 per cent stake in the company for Rs 637 crore through open market transactions.

The buyers included over two dozen funds such as UTI Mutual Fund (MF), Aditya Birla Sun Life MF, Franklin Templeton MF, ICICI Prudential MF, Mirae Asset MF, Abu Dhabi Investment Authority and Tata AIA Life Insurance Company, among others.

Aayush Agrawal Trust and Ravi Agrawal Trust offloaded a total of 54,92,846 shares, amounting to 4.3 per cent stake in Ajanta Pharma, as per block deal data with the National Stock Exchange (NSE).

The shares were offloaded at an average price of Rs 1,160.1 per scrip, taking the transaction value to Rs 637.22 crore.

Following the stake sale, the promoter and promoter group entities' shareholding has come down to 66.18 per cent from 70.48 per cent.

Ajanta Pharma's shares closed 5.22 per cent higher at Rs 1,233 apiece on NSE.

Mumbai-based Ajanta Pharma is a speciality pharmaceutical formulation company.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Ajanta Pharmastock markets

First Published: Dec 22 2022 | 10:35 PM IST

Next Story